Non-Small Cell Lung Cancer

Title Average Ratingsort ascending
Psorinum, the anti cancer miracle from India. 92.73%
Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach. 90.00%
Chlamydia pneumoniae infection and lung cancer risk: a meta-analysis. 90.00%
Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: a randomized controlled 80.00%
Enhancement of the efficacy of cancer chemotherapy by the pineal hormone melatonin and its relation with the psychospiritual sta 80.00%
Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients .... 80.00%
Pilot study of a specific dietary supplement in tumor-bearing mice and in stage IIIB and IV non-small cell lung cancer patients. 80.00%
Dihydroartemisinin (DHA) induces caspase-3-dependent apoptosis in human lung adenocarcinoma ASTC-a-1 cells. 80.00%
Cancer Psychotherapy according to Dr. Frederick B Levenson 73.33%
Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm). 70.00%
Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. 70.00%
Randomized phase II clinical trial of chemo-immunotherapy in advanced nonsmall cell lung cancer. 70.00%
Systemic chemotherapy using paclitaxel and carboplatin plus regional hyperthermia and hyperbaric oxygen treatment for NSCLC. 70.00%
Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. 70.00%
Correlation of immune responses and survival in a phase II study of belagenpumatucel-L in non-small cell lung cancer. 60.00%
MET in small cell lung carcinoma (SCLC): Effects of a MET inhibitor in SCLC cell lines and prognostic role of MET status in pati 50.00%
Long-term safety of BLP25 liposome vaccine (L-BLP25) in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). 50.00%
Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer 50.00%
A phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell.. 50.00%
Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. 40.00%
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplat 40.00%
Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced... 30.00%